摘要
目的:探讨玻璃体切割联合白内障手术治疗增殖性糖尿病视网膜病变的疗效。方法:选择2013年1月至2016年6月我院接诊的90例增殖性糖尿病视网膜病变患者,通过随机数表法分为观察组(n=45)和对照组(n=45)。对照组使用玻璃体切割术+晶状体切除术,观察组使用玻璃体切割术+超声乳化吸除术。比较两组最佳矫正视力、泪液白介素(IL)-2、角膜荧光素染色(FL)、泪膜破裂时间(BUT)以及泪液分泌试验(SIt)的结果以及并发症的发生情况。结果:手术后,观察组最佳矫正视力明显优于对照组(P<0.05),泪液IL-2水平明显高于对照组(P<0.05),FL显著低于对照组,BUT、SIt明显高于对照组(P<0.05),囊膜浑浊、虹膜新生血管、角膜水肿、干眼症的发生率均显著低于对照组(P<0.05)。结论:玻璃体切割联合超声乳化吸除术治疗增殖性糖尿病视网膜病变患者的效果显著,可促进术后视力恢复,改善泪液分泌,并减少并发症。
Objective：To study the clinical efficacy of vitrectomy combined with cataract surgery enin the treatmt of proliferative diabetic retinopathy.Methods：90 patients of proliferative diabetic retinopathy who were treated from January 2013 to June 2016 in our hospital were selected.According to random number table,those patients were divided into the observation group （n=45） and the control group （n=45）.The control group was treated with vitrectomy＋lentectomy,while the observation group was treated with vitrectomy＋ phacoemulsification.Then the best corrected visual acuity,tear interleukin （IL）-2,fluorescein （FL）,breakup time of tear film （BUT） and Schirmer test（SIt） and incidence of complications were compared.Results：After operation,the best corrected visual acuity of observation group was better than that of the control group（P〈0.05）;the tear IL-2 level in the observation group was significantly higher than that of the control group （P〈0.05）;the FL in the observation group was significantly lower than that of the control group,the BUT and SIt were significantly higher than those of the control group （P 〈 0.05）;the incidence rate of capsular opacity,iris neovascularization,corneal edema,xerophthalmia in the observation group was significantly lower than that of the control group （P 〈0.05）.Conclusion：Vitrectomy combined with phacoemulsification was effective for proliferative diabetic retinopathy,which could promote the recovery of visual acuity after surgery,improvement of tear secretio and decrease the complications.
出处
《现代生物医学进展》
CAS
2017年第25期4959-4962,共4页
Progress in Modern Biomedicine
基金
国家卫生部中医药管理科研基金项目(9211D4)
